Page last updated: 2024-12-11

naltrindole benzofuran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

naltrindole benzofuran: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5486827
CHEMBL ID100940
CHEBI ID177440
SCHEMBL ID1240717
MeSH IDM0188195

Synonyms (29)

Synonym
CHEBI:177440
(1s,2s,13r,21r)-22-(cyclopropylmethyl)-11,14-dioxa-22-azaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol
gtpl1640
PDSP2_001551
ntb ,
naltrindole benzofuran
naltriben
4,8-methano-5h-bisbenzofuro(3,2-e:2',3'-g)isoquinoline-1,8a(9h)-diol, 7-(cyclopropylmethyl)-6,7,8,14b-tetrahydro-, (8r-(4bs*,8alpha,8beta,14bbeta))-
HMS2089G18
CHEMBL100940
111555-58-9
C20166
cas_111555-58-9
naltrindolebenzofuran
bdbm82552
unii-rxg719f189
rxg719f189 ,
[3h]naltriben
gtpl3828
[3h]-naltriben
AB00691672-07
SCHEMBL1240717
naltriben mesylate
DTXSID80912218
Q12746295
4,8-methano-8ah-bisbenzofuro(3,2-e:2',3'-g)isoquinoline-1,8a-diol, 7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bs,8r,8as,14br)-
4,8-methano-8ah-bisbenzofuro(3,2-e:2',3'-g)isoquinoline-1,8a-diol, 7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (8r-(4bs*,8.alpha.,8a.beta.,14b.beta.))-
(4bs,8r,8as,14br)-7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-4,8-methano-8ah-bisbenzofuro(3,2-e:2',3'-g)isoquinoline-1,8a-diol
(4bs,8r,8as,14br)-7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-8ah-4,8-methanobis[1]benzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"03 microgram of DAMGO resulting in a steeper dose-response relationship."( Evidence for delta opioid receptor subtypes in rat spinal cord: studies with intrathecal naltriben, cyclic[D-Pen2, D-Pen5] enkephalin and [D-Ala2, Glu4]deltorphin.
Hammond, DL; Stewart, PE, 1993
)
0.29
" Once rats had acquired the ethanol-saline discrimination, ethanol dose-response tests were conducted with 15-min pretest injections."( Opiate delta-2-receptor antagonist naltriben does not alter discriminative stimulus effects of ethanol.
Carl, K; Garrett, KM; Holloway, FA; Mhatre, MC, 2000
)
0.31
" NTB (30 nM) shifted the dose-response curve of DAMGO to the right and attenuated the maximal effect."( Pharmacological effects of naltriben as a ligand for opioid mu and kappa receptors in rat cerebral cortex.
Cho, KP; Kim, KW; Shin, BS; Son, Y, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
morphinane alkaloidAn isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorMus musculus (house mouse)Ke0.00070.00010.14726.1080AID148813; AID148930
Delta-type opioid receptorRattus norvegicus (Norway rat)Activity0.00000.00000.11931.2200AID310939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1346406Rat delta receptor (Opioid receptors)1999British journal of pharmacology, Oct, Volume: 128, Issue:3
Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.
AID1346361Human delta receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346361Human delta receptor (Opioid receptors)1991The Journal of pharmacology and experimental therapeutics, May, Volume: 257, Issue:2
Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes.
AID1346373Mouse delta receptor (Opioid receptors)1994Molecular pharmacology, Feb, Volume: 45, Issue:2
Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.
AID1346364Human mu receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346329Human kappa receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID235331Selectivity ratio of mu opioid receptor to delta opioid receptor1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.
AID227054Competitive inhibition of Morphine on Guinea pig ileal longitudinal muscle for the opioid receptor mu at 200 nM1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID148118Selectivity ratio is Ki value of opioid receptor kappa to that of delta-opioid receptor1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID148116Selectivity ratio is IC50 value of opioid receptor kappa to that of opioid receptor delta1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID149025Selectivity ratio is IC50 value of mu-opioid receptor to that of delta-opioid receptor1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID609328Antimalarial activity against chloroquine-resistant Plasmodium chabaudi infected in mouse assessed as parasitemia at 10 mg/kg, po administered for 3 consecutive days2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Opioid δ₁ receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant Plasmodium chabaudi.
AID624621Specific activity of expressed human recombinant UGT2B7Y2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID148813Antagonistic activity against Opioid receptor delta 1 using [D-Ala2,D-Leu5]enkephalin in mouse vas deferens preparation1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.
AID150029Compound was evaluated for antagonist potency in guinea pig ileum preparation using morphine (Opioid receptor mu 1)1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.
AID147970Antagonistic potency at opioid receptor kappa (200 nM) (Ke =IC50 in the presence of antagonist divided by the control IC50 value)1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID232963Ke selectivity ratio (mu/delta) of the compound1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.
AID227056Competitive inhibition of the DADLE on mouse vas deferens for the opioid receptor delta at 20 nM1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID149004Antagonistic potency at opioid receptor mu (200 nM) (Ke =IC50 in the presence of antagonist divided by the control IC50 value)1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID1129814Antagonist activity at delta opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 30 mins in presence of agonist DPDPE2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity.
AID128811Antagonism of kappa2 opioid agonist (bremazocine)-induced antinociception upon intrathecal administration in mice at a dose of 50 pmol2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.
AID609329Reversal of chloroquine-resistance in Plasmodium chabaudi infected in mouse at 10 mg/kg, po coadministered with chloroquine 3 mg/kg, iv administered for 3 consecutive days measured on day 42011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Opioid δ₁ receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant Plasmodium chabaudi.
AID149196Compound was evaluated for the binding affinity to opioid receptor delta using [3H]DADLE as radioligand in guinea pig brain membrane1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID1461556Antimicrobial activity against Trichomonas vaginalis after 48 hrs by neutral red staining based invert microscopic analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.
AID232962Ke selectivity ratio (kappa/delta) of the compound1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.
AID148836Antagonistic activity against Opioid receptor kappa 1 using ethylketazocine in guinea pig ileum preparation1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.
AID624620Specific activity of expressed human recombinant UGT2B7H2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID235328Selectivity ratio of kappa opioid receptor to delta opioid receptor1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.
AID227051Competitive inhibition of Ethylketazocine on Guinea pig ileal longitudinal muscle for the opioid receptor kappa at 200 nM1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID149016Compound was evaluated for the binding affinity to Opioid receptor mu using [3H]DAMGO as radioligand in guinea pig brain membrane1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID310939Displacement of [3H]naltrindole from rat delta opioid receptor expressed in C6 cells2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.
AID149211Antagonistic potency at opioid receptor delta (20 nM) (Ke =IC50 in the presence of antagonist divided by the control IC50 value)1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID148961Compound was evaluated for antagonist potency in guinea pig ileum preparation using ethylketazocine (Opioid receptor kappa 1)1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.
AID128677Antagonism of delta1 opioid agonist (DPDPE)-induced antinociception upon intrathecal administration in mice at a dose of 50 pmol2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.
AID149910Compound was evaluated for binding affinity at Opioid receptor delta 1 in guinea pig brain membranes1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.
AID149283Compound was evaluated for binding affinity of Opioid receptor kappa 1 in guinea pig brain membranes1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.
AID148041Compound was evaluated for binding affinity at Opioid receptor mu 1 in guinea pig brain membranes1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.
AID128805Antagonism of kappa1 opioid agonist (U-50,488)-induced antinociception upon intrathecal administration in mice at a dose of 50 pmol2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.
AID150012Antagonistic activity against Opioid receptor mu 1 using morphine in guinea pig ileum preparation1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.
AID149026Selectivity ratio is Ki value of mu-opioid receptor to that of delta-opioid receptor1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID147983Compound was evaluated for the binding affinity to opioid receptor kappa using [3H]-EK as radioligand in guinea pig brain membrane1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
AID128683Antagonism of delta2 opioid agonist (deltorphin II)-induced antinociception upon intrathecal administration in mice at a dose of 50 pmol2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.
AID148930Compound was evaluated for antagonist potency in the mouse vas deferens preparation using [D-Ala2,D-Leu5]enkephalin (Opioid receptor delta 1)1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (101)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.99)18.7374
1990's50 (49.50)18.2507
2000's32 (31.68)29.6817
2010's15 (14.85)24.3611
2020's3 (2.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.16 (24.57)
Research Supply Index4.63 (2.92)
Research Growth Index6.79 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.98%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other101 (99.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]